Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Gets NY State Permit for microRNA Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics has received a clinical laboratory permit from the New York State Department of Health allowing the firm to offer its microRNA-based tests to physicians and patients in the state.

The firm currently sells three tests — the miRview meso, miRview mets, and miRview squamous — that are run at its own Philadelphia-based CAP-accredited, CLIA-certified lab.

The miRview meso test differentiates lung cancer from mesothelioma; miRview mets is designed to determine the source of cancers of unknown primary origin; and miRview squamous is designed to differentiate squamous from non-squamous non-small cell lung cancer.

Rehovot, Israel-based Rosetta said that it also is working with the NYS DOH to gain approval for its second-generation versions of the tests.

Rosetta Genomics President and CEO Kenneth Berlin noted that the firm's tests are now available to residents of all 50 states in the US.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.